BRPI0924549A2 - nano fotomedicamentos como alvo para terapia fotodinâmica do câncer - Google Patents

nano fotomedicamentos como alvo para terapia fotodinâmica do câncer

Info

Publication number
BRPI0924549A2
BRPI0924549A2 BRPI0924549A BRPI0924549A BRPI0924549A2 BR PI0924549 A2 BRPI0924549 A2 BR PI0924549A2 BR PI0924549 A BRPI0924549 A BR PI0924549A BR PI0924549 A BRPI0924549 A BR PI0924549A BR PI0924549 A2 BRPI0924549 A2 BR PI0924549A2
Authority
BR
Brazil
Prior art keywords
photomedicines
nano
targeted
cancer therapy
photodynamic cancer
Prior art date
Application number
BRPI0924549A
Other languages
English (en)
Inventor
Dominic James Robinson
Henricus Johannes Cornelius Maria Sterenborg
Manzoor Koyakutty
Shantikumar Nair
Slavka Kascakova
Original Assignee
Amrita Vishwa Vidyapeetham University
Univ Erasmus Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrita Vishwa Vidyapeetham University, Univ Erasmus Medical Ct filed Critical Amrita Vishwa Vidyapeetham University
Publication of BRPI0924549A2 publication Critical patent/BRPI0924549A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BRPI0924549A 2009-06-12 2009-06-12 nano fotomedicamentos como alvo para terapia fotodinâmica do câncer BRPI0924549A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2009/050337 WO2010143942A1 (en) 2009-06-12 2009-06-12 Targeted nano-photomedicines for photodynamic therapy of cancer

Publications (1)

Publication Number Publication Date
BRPI0924549A2 true BRPI0924549A2 (pt) 2016-04-26

Family

ID=42184028

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924549A BRPI0924549A2 (pt) 2009-06-12 2009-06-12 nano fotomedicamentos como alvo para terapia fotodinâmica do câncer

Country Status (9)

Country Link
US (2) US20120184495A1 (pt)
EP (1) EP2440247B1 (pt)
JP (1) JP5662431B2 (pt)
CN (1) CN102573910B (pt)
AU (1) AU2009347929A1 (pt)
BR (1) BRPI0924549A2 (pt)
ES (1) ES2627420T3 (pt)
IL (1) IL216913A0 (pt)
WO (1) WO2010143942A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070197A1 (en) 2015-10-19 2017-04-27 Immunolight, Llc X-ray psoralen activated cancer therapy (x-pact)
US10596387B2 (en) * 2007-04-08 2020-03-24 Immunolight, Llc. Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties
US10441810B2 (en) 2007-04-08 2019-10-15 Immunolight, Llc X-ray psoralen activated cancer therapy (X-PACT)
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
CN102350277B (zh) * 2011-06-16 2013-12-18 中国科学院苏州纳米技术与纳米仿生研究所 具双模式成像与光动力活性功能的复合微球及其制备方法
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
CN102727892A (zh) * 2012-07-06 2012-10-17 陈智毅 一种靶向顺磁性稀土离子光敏探针及其制备方法
CN103721257B (zh) 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 光敏素催化分解过氧化氢系列药物
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure
EP2996677B1 (en) * 2013-05-18 2019-11-20 National Chung-Hsing University Photosensitizer particles for medical imaging and/or photodynamic therapy
JP6684215B2 (ja) 2013-08-28 2020-04-22 ピーシーアイ バイオテック エイエス 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
US10124072B2 (en) 2013-09-18 2018-11-13 Caliper Life Sciences, Inc. In-vivo reactive species imaging
FR3012040B1 (fr) 2013-10-23 2015-12-04 Synchrotron Soleil Compose radio-luminescent pour la radiotherapie et la phototherapie dynamique de tumeurs profondes et dispositif de phototherapie dynamique de tumeurs profondes
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015164487A1 (en) * 2014-04-22 2015-10-29 Immunolight, Llc Interior energy-activation of photo-reactive species inside a medium or body using an x-ray source emitting low energy x-rays as initiation energy source
CN104383539B (zh) * 2014-10-28 2017-02-08 中国科学院上海硅酸盐研究所 一种细胞核靶向生物光子诊疗剂及其制备方法
CN104331919B (zh) * 2014-11-02 2017-04-19 北京理工大学 光动力治疗中投光方向的优化方法
CN104528636B (zh) * 2014-12-18 2016-04-27 上海纳米技术及应用国家工程研究中心有限公司 一种磁性颗粒表面修饰金纳米颗粒的功能化方法
CA3021809A1 (en) * 2015-05-11 2016-11-17 Dicronis Sagl Compositions for circulatory system visualization
CN106620893B (zh) * 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
CN105802611B (zh) * 2016-04-20 2018-07-27 复旦大学 一种比率型纳米硅量子点荧光探针及其制备方法和应用
US10944398B2 (en) * 2016-09-30 2021-03-09 Uchicago Argonne, Llc Systems and methods for ultrafast plasmonic response in doped, colloidal nanostructures
CN106974882A (zh) * 2017-03-07 2017-07-25 常州大学 一种核壳结构的聚吡咯/介孔二氧化硅/石墨烯量子点纳米复合材料在药物控释中的应用
CN106727274A (zh) * 2017-03-07 2017-05-31 常州大学 一种核壳结构的聚吡咯/介孔二氧化硅/石墨烯量子点纳米复合材料的制备方法
AU2018251788B2 (en) 2017-04-12 2025-04-10 Aura Biosciences, Inc. Targeted combination therapy
CN107281163B (zh) * 2017-07-05 2020-08-14 郑州大学 羧基化合物在促进载药纳米粒微球口服吸收方面的应用
KR20190013289A (ko) * 2017-08-01 2019-02-11 순천대학교 산학협력단 수용성 키토산을 포함하는 나노광증감제
CN109381428B (zh) * 2017-08-10 2022-11-08 复旦大学 用于肿瘤光动力治疗联合免疫治疗的纳米制剂
WO2020081581A1 (en) * 2018-10-16 2020-04-23 The Regents Of The University Of Colorado, A Body Corporate Chemiluminescent and fluorescent nanoparticle for optical imaging of cancer
CN110003888B (zh) * 2019-04-11 2022-03-22 苏州大学 一种荧光纳米探针及其制备方法
CN111467507A (zh) * 2020-03-20 2020-07-31 中国科学院苏州生物医学工程技术研究所 功能化双模态成像纳米探针、其制备方法及在主动脉瘤诊断中的应用
CN113512421B (zh) * 2020-03-26 2023-07-18 重庆邮电大学 一种碳量子点-铁离子复合荧光材料及其制备方法
CN115400224A (zh) * 2021-05-28 2022-11-29 北京大学第三医院（北京大学第三临床医学院） 一种超声压电催化产生氧气和活性氧的钛酸钡及其制备方法和应用
US11801395B2 (en) * 2021-07-28 2023-10-31 Lumeda Inc. Optical applicator feature optimizer
CN113662918B (zh) * 2021-08-05 2023-06-20 南京理工大学 一种pH响应型量子点-聚合物靶向药物载体
CN119136720A (zh) * 2022-06-20 2024-12-13 奥林巴斯株式会社 图像处理装置、光治疗系统、图像处理方法、图像处理程序以及光治疗方法
CN115350286A (zh) * 2022-07-07 2022-11-18 同济大学 毛绒状磁-铂纳米粒子制备及负载于细胞中的方法与应用
CN116808209B (zh) * 2023-06-30 2025-08-22 广西大学 光敏剂PEG-In2O3/Fe及其合成方法以及应用
CN117511538B (zh) * 2023-11-02 2025-09-26 苏州大学 一种ucnp-qd-gnp组装体纳米探针及其应用
WO2025257139A1 (en) * 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Functionalized inorganic oxide or hydroxide for use against enveloped viruses
CN121731466B (zh) * 2026-03-02 2026-06-19 浙江医院 一种x射线响应型中性粒细胞负载纳米维替泊芬及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5257970A (en) * 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy
EP1125577B1 (en) * 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
WO1996035677A1 (en) * 1995-05-10 1996-11-14 G.D. Searle & Co. Nitric oxide synthase inhibitors derived from cyclic amidines
ATE255583T1 (de) * 1998-07-10 2003-12-15 Meiji Seika Kaisha Metallkomplexe von chlorinderivaten zum abschirmen von röntgenstrahlen
CA2599304C (en) * 2004-02-27 2014-07-08 Peter Maccallum Cancer Institute Cell targeting conjugates
US20050220714A1 (en) * 2004-04-01 2005-10-06 Susan Kauzlarich Agents for use in magnetic resonance and optical imaging
DE602005024437D1 (de) * 2004-12-03 2010-12-09 Univ Utah Res Found Mrt-geführte photodynamische therapie gegen krebs
RU2007127314A (ru) * 2004-12-17 2009-01-27 Конинклейке Филипс Электроникс Н.В. (Nl) Контрастные средства или терапевтические средства направленной доставки для молекулярной визуализации и терапии
EP1973575B1 (en) * 2005-12-22 2019-07-24 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
KR101035269B1 (ko) * 2007-04-23 2011-05-26 한국과학기술연구원 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
WO2008133598A1 (en) * 2007-04-30 2008-11-06 Agency For Science, Technology And Research Forming crosslinked-glutathione on nanostructure
WO2009038659A2 (en) * 2007-09-14 2009-03-26 Health Research, Inc. Organically modified silica nanoparticles with covalently incorporated photosensitizers for drug delivery in photodynamic therapy
WO2009077908A1 (en) * 2007-12-14 2009-06-25 University Of Lausanne Colloidal particle comprising multivalent cyclic anions
US20100055440A1 (en) * 2008-08-27 2010-03-04 Seoul National University Industry Foundation Composite nanoparticles

Also Published As

Publication number Publication date
EP2440247B1 (en) 2017-03-08
WO2010143942A1 (en) 2010-12-16
CN102573910A (zh) 2012-07-11
US20120184495A1 (en) 2012-07-19
JP2012529500A (ja) 2012-11-22
EP2440247A1 (en) 2012-04-18
JP5662431B2 (ja) 2015-01-28
CN102573910B (zh) 2015-08-26
AU2009347929A1 (en) 2012-01-19
US20220296714A1 (en) 2022-09-22
IL216913A0 (en) 2012-02-29
ES2627420T3 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
IL216913A0 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
LT3192529T (lt) Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
BR112012005594A2 (pt) tratamento de câncer
GB0916666D0 (en) Photodynamic therapy device
HRP20181385T1 (hr) Ciljanje abcb5 za terapiju raka
EP2422846A4 (en) CORPUSCULAR RADIATION THERAPY APPARATUS
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012002797A2 (pt) tratamento de câncer de próstata
PT2434891T (pt) Métodos para tratamento de cancro e afeções não neoplásicas
PT2515855E (pt) Terapêutica de combinação para dpoc
IL224370B (en) Combination treatment for prostate carcinoma
HUE046667T2 (hu) Rák kombinatív kezelése
HRP20170972T1 (hr) Kombinacijska terapija afukoziliranog cd20-protutijela s bendamustinom
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
EP2432539A4 (en) Hyperthermia assisted radiation therapy
EP2872120A4 (en) TARGETED THERAPEUTIC NANOPARTICLES
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BR112014000021A2 (pt) terapia direcionada para egfr
BR112013023452A2 (pt) combinação de oligonucleotídeo anti-clusterina com inibidor de hsp90 para o tratamento de câncer de próstata

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 41/00 (2006.01), A61K 47/69 (2017.01), A61K 4